Clinical Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Clinical Cancer Research 13, 7022-7028, December 1, 2007. doi: 10.1158/1078-0432.CCR-07-1420
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lo, K. C.
Right arrow Articles by Cowell, J. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lo, K. C.
Right arrow Articles by Cowell, J. K.

Imaging, Diagnosis, Prognosis

Gain of 1q Is a Potential Univariate Negative Prognostic Marker for Survival in Medulloblastoma

Ken C. Lo1, Changxing Ma2, Brian N. Bundy2, Scott L. Pomeroy3, Charles G. Eberhart4 and John K. Cowell1

Authors' Affiliations: Departments of 1 Cancer Genetics and 2 Biostatistics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York; 3 Department of Neurology, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts; and 4 Department of Pathology and Oncology, School of Medicine, Johns Hopkins University, Baltimore, Maryland

Requests for reprints: John K. Cowell, Department of Cancer Genetics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263. Phone: 716-845-5714; Fax: 716-845-1698; E-mail: John.Cowell{at}RoswellPark.org.

Purpose: Tumor risk stratification during diagnosis is paramount for children with medulloblastomas, primarily because very young patients (<3 years) suffer cognitive deficits from radio- and chemotherapy sequelae. Thus, distinguishing tumors that are biologically more aggressive is essential for medulloblastoma management to maximize the delay in radiation treatment without adversely affecting survival outcome. In this context, current strategies for risk assessment, which are based on clinical parameters, remain unsatisfactory.

Experimental Design: Array-based comparative genomic hybridization (aCGH) was used to identify chromosomal copy number abnormalities in a cohort of 49 medulloblastoma tumors. Based on the karyotypes generated from aCGH analysis, each tumor was scored for copy number abnormalities, and the log-rank test was used to evaluate whether any cytogenetic events were associated with survival.

Results: A single copy gain of 1q was shown to be a negative prognostic marker for survival in medulloblastomas with high statistical significance (P < 0.0001, log-rank test).

Conclusion: A gain of 1q provides a potential means of predicting overall survival in medulloblastoma.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.